Varenicline
- Generic Name
- Varenicline
- Brand Names
- Champix, Chantix, Tyrvaya
- Drug Type
- Small Molecule
- Chemical Formula
- C13H13N3
- CAS Number
- 249296-44-4
- Unique Ingredient Identifier
- W6HS99O8ZO
- Background
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors.
On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced.
- Indication
For use as an aid in smoking cessation.
Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- Smoking, Cessation
Understanding Disparities in Quitting in African American and White Smokers
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- Nikki Nollen, PhD, MA
- Target Recruit Count
- 449
- Registration Number
- NCT01836276
- Locations
- 🇺🇸
Swope Health Central, Kansas City, Missouri, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers
- Conditions
- Interventions
- First Posted Date
- 2013-03-07
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Duke University
- Target Recruit Count
- 376
- Registration Number
- NCT01806779
- Locations
- 🇺🇸
Duke Center for Smoking Cessation, Winston-Salem, North Carolina, United States
The Canadian HIV Quit Smoking Trial: Tackling the Co-morbidities of Depression and Cardiovascular Disease in HIV+ Smokers
- First Posted Date
- 2013-02-27
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 256
- Registration Number
- NCT01800019
- Locations
- 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers
- Conditions
- Interventions
- First Posted Date
- 2013-01-18
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 300
- Registration Number
- NCT01771627
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Extended Varenicline Treatment for Smoking Among Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2012-12-28
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 207
- Registration Number
- NCT01756885
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Varenicline for Nicotine Dependence Among Those With HIV/AIDS
- Conditions
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 179
- Registration Number
- NCT01710137
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Efficacy of Varenicline on Smoking Cessation at the Acute Phase of an Exacerbation of Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- University Hospital, Brest
- Target Recruit Count
- 83
- Registration Number
- NCT01694732
- Locations
- 🇫🇷
Caremeau Hospital, Nimes, France
🇫🇷Poitiers Hospital, Poitiers, France
🇫🇷CHU Angers, Angers, France
A Phase II Trial of Varenicline for the Treatment of Cocaine Dependence
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 156
- Registration Number
- NCT01680887
- Locations
- 🇺🇸
University of Pennsylvania Treatment Research Center, Philadelphia, Pennsylvania, United States
Varenicline for Light Smokers
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 93
- Registration Number
- NCT01639560
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
The Effect of Varenicline on D2/D3 Receptor Binding in Smokers
- First Posted Date
- 2012-07-02
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 8
- Registration Number
- NCT01632189
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.